Medtronic Permanent Lead Introducer
Medtronic Vascular
FDA Clearance Information
The Medtronic Permanent Lead Introducer was cleared by the FDA via the 510(k) pathway on December 24, 1985. It is manufactured by Medtronic Vascular and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Facilitation of the introduction and placement of permanent cardiac pacing leads.
- Use during procedures requiring placement of a permanent pacemaker or pacing lead.
Clinical Applications
- Introducing a permanent pacing lead through a venous access site.
- Helping position a pacing lead within the heart during pacemaker implantation.
- Supporting lead placement in procedures for cardiac conduction or rhythm disorders when permanent pacing is indicated.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The introducer must be compatible with the selected pacing lead, guidewire, and venous access system; available sizes and configurations depend on the specific catalog number and labeling.
- The device is used under fluoroscopic or other appropriate imaging guidance, usually through venous access such as the cephalic, axillary, or subclavian vein.
- Patients with active infection, severe bleeding risk, venous occlusion, or unsuitable vascular anatomy may require an alternative approach or may not be candidates.
- MRI safety cannot be determined from the generic device name alone. MRI eligibility depends on the exact introducer, implanted lead and pacemaker system, and current manufacturer labeling; the introducer itself is generally removed after the procedure.
- The introducer is a sterile, single-use device and should not be reused or resterilized unless the current FDA-cleared labeling specifically permits it.
Frequently Asked Questions
What are the clinical indications for Medtronic Permanent Lead Introducer?
The device is indicated for use in cardiac resynchronization therapy, particularly in patients with heart failure and intraventricular conduction disorders.
What outcomes have been reported in clinical studies?
Studies have reported improvements in left ventricular ejection fraction and reduced complications associated with traditional pacemaker leads.
What complications have been reported?
Reported complications include procedural challenges and issues related to lead placement, though the device reduces lead- and pocket-associated complications.